HLA-A30

HLA-A30
(MHC Class I, A cell surface antigen)
HLA-A30
-
Protein transmembrane receptor/ligand
Structure αβ heterodimer
Subunits HLA-A*30--, β2-microglobulin
Older names "A19"
-
subtype allele Available structures
A30.3 *3001
A30.2 *3002
rare alleles
A30.4 *3004
Alleles link-out to IMGT/HLA database at EBI

HLA-A30 (A30) is a human leukocyte antigen serotype within HLA-A serotype group. The serotype is determined by the antibody recognition of α30 subset of HLA-A α-chains. For A30, the alpha "A" chain are encoded by the HLA-A*30 allele group and the β-chain are encoded by B2M locus.[1] A30 and A*30 are almost synonymous in meaning. A30 is a split antigen of the broad antigen serotype A19. A30 is a sister serotype of A29A31A32A33, and A74.

Contents

Serotype

A30 recognition of some HLA A*30 gene products[2]
A*30 A30 A19 A31 Sample
allele  %  %  % size (N)
*3001 89 1 3 3517
*3002 93 1 2 2124
*3004 94 0 0   85



Alleles

HLA A*3001 frequencies
 Study population  Freq.
 (in %)[3]
 India West Coast Parsis   16.0
 Mali Bandiagara   14.1
 Zambia Lusaka   14.0
 South Africian Natal Zulu   9.5
 Jordan Amman   9.3
 Pakistan Kalash   9.2
 Zimbabwe Harare Shona   9.1
 China Beijing   9.0
 Kenya   8.4
 Sudanese   6.8
 Kenya Luo   6.4
 India Khandesh Pawra   6.0
 Pakistan Pathan   5.6
 Cameroon Yaounde   5.5
 USA African America   5.0
 Kenya Nandi   4.8
 Tunisia   4.1
 Cameroon Beti   4.0
 China Inner Mongolia   3.9
 Cameroon Sawa   3.8
 China North Han   3.8
 Guinea Bissau   3.8
 Senegal Niokholo Mandenka   3.8
 South Korea (3)   3.5
 India North Delhi   3.3
 Cameroon Bamileke   3.2
 Pakistan Baloch   3.2
 Uganda Kampala   3.1
 Israel Arab Druse   3.0
 China Qinghai Hui   2.7
 USA Hispanic   2.6
 Brazil   2.5
 France South East   2.3
 Iran Baloch   2.2
 Saudi Arabia Guraiat and …   2.1
 USA North American Native…   2.1
 Portugal Centre   2.0
 Romanian   2.0
 Czech Republic   1.9
 Taiwan Hakka   1.8
 USA Asian   1.8
 Brazil Terena   1.7
 Georgia Tibilisi Kurds   1.7
 USA Caucasians (3)   1.7
 China South Han   1.6
 Morocco Nador Metalsa Cla…   1.4
 Croatia   1.3
 Macedonia (4)   1.2
 Mexico Mestizos   1.2
 India Andhra Pradesh Goll…   1.1
 Ireland Northern   1.1
 Mexico Chihuahua State Ta…   1.1
 Mongolia Buriat   1.1
 Pakistan Brahui   1.1
 Portugal North   1.1
 Thailand   1.1
Allele frequencies presented, only
HLA A*3002 frequencies
 Study population  Freq.
 (in %)[3]
 Zambia Lusaka   23.3
 Zimbabwe Harare Shona   14.7
 Senegal Niokholo Mandenka   12.4
 Cameroon Beti   9.5
 Morocco 'Berber' Nador Me…   8.9
 South Africian Natal Zulu   8.5
 Cameroon Sawa   7.7
 Cameroon Bamileke   7.1
 Cameroon Yaounde   6.0
 Kenya Luo   5.9
 USA African Americans (3)   5.8
 Tunisia   5.6
 Cameroon Pygmy Baka   5.0
 Mexico Guadalajara Mestiz…   4.9
 Oman   4.2
 Pakistan Baloch   4.0
 Uganda Kampala   4.0
 Kenya Nandi   3.7
 Mali Bandiagara   3.4
 Pakistan Brahui   3.4
 USA Hispanic   3.4
 Guinea Bissau   3.1
 USA South Texas Hispanics   3.0
 Iran Baloch   2.8
 Sudanese   2.8
 Brazil   2.5
 Portugal Centre   2.0
 Saudi Arabia Guraiat and …   1.9
 USA North American Native…   1.9
 Georgia Tibilisi Kurds   1.7
 Belgium   1.6
 France South East   1.2
 Ireland Northern   1.2
 Macedonia   1.2
 Pakistan Burusho   1.1
 USA Caucasian Bethesda   1.1
Allele frequencies presented, only

Disease association

A*3002 alters Type 1 diabetes risk[4]

References

  1. ^ Arce-Gomez B, Jones EA, Barnstable CJ, Solomon E, Bodmer WF (February 1978). "The genetic control of HLA-A and B antigens in somatic cell hybrids: requirement for beta2 microglobulin". Tissue Antigens 11 (2): 96–112. doi:10.1111/j.1399-0039.1978.tb01233.x. PMID 77067. 
  2. ^ Allele Query Form IMGT/HLA - European Bioinformatics Institute
  3. ^ a b Middleton D, Menchaca L, Rood H, Komerofsky R (2003). "New allele frequency database: http://www.allelefrequencies.net". Tissue Antigens 61 (5): 403–7. doi:10.1034/j.1399-0039.2003.00062.x. PMID 12753660. 
  4. ^ Noble J, Valdes A, Bugawan T, Apple R, Thomson G, Erlich H (2002). "The HLA class I A locus affects susceptibility to type 1 diabetes.". Hum Immunol 63 (8): 657–64. doi:10.1016/S0198-8859(02)00421-4. PMID 12121673.